How much funding has Khloris Biosciences raised?

Khloris Biosciences has disclosed $5M raised across 1 round.

Where is Khloris Biosciences headquartered?

Khloris Biosciences is headquartered in South San Francisco, US.

Khloris Biosciences

South San Francisco, US · Founded 2017 · Delaware corporation

Khloris Biosciences develops iPSC-based cancer vaccines, using induced pluripotent stem cells to trigger a multi-faceted anti-tumor immune response. The company focuses on identifying novel targets and vaccine candidates for cancer treatment.

Biotech Healthtech Longevity

Founders & leadership

Joseph C. WuNamed on SEC filing

Lynne A. BuiCo-Founder, President, CEO, and Chairman of the Board

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 1 round · 2018

▶$5MraisedDec 2018 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Joseph C. WuDirector
Lynne A. BuiExecutive Officer, Director

Amount sold: $5M
Minimum investment: $100K
First sale: Dec 2018
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap

Claris Bio7 shared keywordsClaris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options. Its lead candidate, CSB-001 (oremepermin alfa ophthalmic solution), targets limbal stem cell deficiency (LSCD), a blinding disease, with pivotal studies planned for 2027.

Alumis7 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.

Exelixis7 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

IQVIA7 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.

Chrysalis Biotherapeutics6 shared keywordsChrysalis Biotherapeutics is a clinical-stage biopharmaceutical company developing peptide therapeutics, led by its drug candidate TP508 (Rusalatide acetate, Chrysalin), which activates endothelial and stem cells to repair tissue after severe viral infection or nuclear radiation. Its immediate target is treating mild to moderate acute respiratory distress syndrome (ARDS) to reduce mortality.

Companies competing with Khloris Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Khloris Biosciences do?: Khloris Biosciences develops iPSC-based cancer vaccines, using induced pluripotent stem cells to trigger a multi-faceted anti-tumor immune response. The company focuses on identifying novel targets and vaccine candidates for cancer treatment.
How much funding has Khloris Biosciences raised?: Khloris Biosciences has disclosed $5M raised across 1 round.
Where is Khloris Biosciences headquartered?: Khloris Biosciences is headquartered in South San Francisco, US.